Compared to cytotoxic chemotherapies, the introduction of immunotherapy has changed the paradigm of treatment for patients with multiple myeloma, according to an expert. Dr. Dickran Kazandjian, a ...

Since the recent introduction of new agents and novel combinations of drugs to treat multiple myeloma, patients newly diagnosed with the disease are living longer and are benefitting from three- and ...

Symptoms initially pointed to toxic alcohol ingestion. A recent case study published in Cureus detailed a dramatic presentation of acute multiple myeloma in a patient with acute kidney failure. The ...

- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a ...

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at ...

CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple ...

Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword? Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development.

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The ...

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy 98% overall response rate observed in relapsed/refractory multiple ...

Most patients present with asymptomatic, early disease but are found to have abnormal blood and/or urine tests that lead to the diagnosis. In asymptomatic patients, laboratory findings, including ...